Reductions in neuropsychiatric symptoms after lecanemab treatment and their associations with imaging markers of β-amyloid clearance

Background: Anti–amyloid-β (Aβ) therapies can slow cognitive decline and reduce cerebral amyloid burden in Alzheimer’s disease (AD). Neuropsychiatric symptoms (NPS) are highly prevalent across the disease course and substantially contribute to disability and caregiver burden. However, whether Aβ cle...

Descripció completa

Dades bibliogràfiques

Autors principals:	Yaping Yan, Daoyan Hu, Linlin Kong, Kaicheng Li, Jun Su, Yingzhe Wu, Hongwei Zhan, Hong Zhang, Yidan Sun, Xiaofeng Dou, Peiyu Huang, Jiong Zhou
Format:	Artigo
Idioma:	Inglês
Publicat:	Elsevier 2026-08-01
Col·lecció:	The Journal of Prevention of Alzheimer's Disease
Matèries:	Alzheimer’s disease Lecanemab Neuropsychiatric symptoms Aβ clearance
Accés en línia:	http://www.sciencedirect.com/science/article/pii/S2274580726001251
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!